Abstract
Discovery of 5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamides as a new class of malonyl-coenzyme A decarboxylase (MCD) inhibitors is described. tert-Butyl 3-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamido)butanoate (5, CBM-301940) exhibited excellent potency and in vivo PK/ADME properties. It is the most powerful stimulant of glucose oxidation reported to date in isolated working rat hearts. Compound 5 improved the cardiac efficiency and function in a rat heart global ischemia/reperfusion model, suggesting MCD inhibitors may be useful for the treatment of ischemic heart diseases.
MeSH terms
-
Administration, Oral
-
Animals
-
Biological Availability
-
Carboxy-Lyases / antagonists & inhibitors*
-
Cardiotonic Agents / chemical synthesis*
-
Cardiotonic Agents / pharmacokinetics
-
Cardiotonic Agents / pharmacology
-
Crystallography, X-Ray
-
Isoxazoles / chemical synthesis*
-
Isoxazoles / pharmacokinetics
-
Isoxazoles / pharmacology
-
Molecular Conformation
-
Myocardial Ischemia / drug therapy
-
Myocardial Ischemia / physiopathology
-
Myocardial Reperfusion
-
Rats
-
Rats, Sprague-Dawley
-
Stereoisomerism
-
Structure-Activity Relationship
Substances
-
Cardiotonic Agents
-
Isoxazoles
-
tert-butyl 3-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamido)butanoate
-
Carboxy-Lyases
-
malonyl-CoA decarboxylase